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Abstract
Introduction: Percent mammographic density (PMD) adjusted for age and body mass index is one of the
strongest risk factors for breast cancer and is known to be approximately 60% heritable. Here we report a finding
of an association between genetic ancestry and adjusted PMD.
Methods: We selected self-identified Caucasian women in the California Pacific Medical Center Research Institute
Cohort whose screening mammograms placed them in the top or bottom quintiles of age-adjusted and body
mass index-adjusted PMD. Our final dataset included 474 women with the highest adjusted PMD and 469 with the
lowest genotyped on the Illumina 1 M platform. Principal component analysis (PCA) and identity-by-descent
analyses allowed us to infer the women’s genetic ancestry and correlate it with adjusted PMD.
Results: Women of Ashkenazi Jewish ancestry, as defined by the first principal component of PCA and identity-by-
descent analyses, represented approximately 15% of the sample. Ashkenazi Jewish ancestry, defined by the first
principal component of PCA, was associated with higher adjusted PMD (P = 0.004). Using multivariate regression to
adjust for epidemiologic factors associated with PMD, including age at parity and use of postmenopausal hormone
therapy, did not attenuate the association.
Conclusions: Women of Ashkenazi Jewish ancestry, based on genetic analysis, are more likely to have high age-
adjusted and body mass index-adjusted PMD. Ashkenazi Jews may have a unique set of genetic variants or
environmental risk factors that increase mammographic density.
Introduction
Percent mammographic density (PMD) is the proportion
of radiographically dense breast tissue as a fraction of the
entire breast and can be calculated from a two-dimensional
mammogram image [1-3] or as a fraction of the entire
volume of the breast [4-13]. PMD is a strong risk factor for
breast cancer; women of the same age and body mass
index (BMI) in the upper quartile of PMD have a fourfold
to sixfold higher risk of breast cancer than women in the
lower quartile [1,3,14-20].
Many of the risk factors for high PMD are also risk
factors for breast cancer, including late parity and use of
postmenopausal hormone therapy with estrogen and
progestin [3,21]. However, reproductive and hormonal
factors account for a small proportion of the variation in
PMD [21], and PMD remains a risk factor for breast can-
cer when adjusting for these factors [22,23]. Approxi-
mately 60% of the variance in PMD is heritable [24-27]
and some genetic variants that are associated with breast
cancer risk are also associated with increased PMD [28].
Both linkage and genome-wide association studies have
been used to search for genetic determinants of PMD
[29-33]. To date, the majority of heritability remains
unexplained; for example, a recent genome-wide associa-
tion study found SNP variants accounting for only 0.5%
of the variance in PMD [30].
Identifying an ethnic population with higher PMD
may have implications for breast cancer risk in that
population and could open new avenues to map genes
for this trait. We genotyped US Caucasian women at
the extremes of adjusted PMD and evaluated the asso-
ciation between genetic ancestry and adjusted PMD,
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uncovering a previously unknown association between
Ashkenazi Jewish ancestry and adjusted PMD.
Methods
Study sample
Study subjects were selected from 4,511 women enrolled
in the California Pacific Medical Center Breast Health
Cohort who underwent screening mammography between
January 2004 and April 2006 and consented to provide
blood specimens between July 2004 and June 2007. The
California Pacific Medical Center Breast Health Cohort is
linked to the San Francisco Mammography Registry, part
of the NCI Breast Cancer Surveillance Consortium that
collects demographic and risk factor data on women
receiving mammography.
The questionnaire includes information on age, race,
height, weight, parity history, postmenopausal hormone
therapy use, personal history of breast cancer, and family
history of breast cancer (in mother, sister, or daughter).
The questionnaire allows the following categories for race/
ethnicity: White/Caucasian, Black/African American,
Hispanic/Latina, American Indian, Chinese, Japanese,
Filipina, Vietnamese, Other Asian and Other; it did not
include Ashkenazi Jewish as a category. Only women who
reported White/Caucasian race/ethnicity were included in
this study. We excluded women who reported a personal
history of breast cancer.
All participants gave informed consent to participate
in the research. The study was approved by the Univer-
sity of California, San Francisco and the California Paci-
fic Medical Center institutional review boards.
Measurement of mammographic density
PMD was calculated from craniocaudal digitized film
mammograms using single X-ray absorptiometry (SXA),
as described in [4]. In brief, the method makes two sepa-
rate calculations: the total volumetric density and the total
breast density. PMD is calculated as the quotient of total
volumetric density and total breast volume. To calculate
the total volumetric density, a calibrated phantom refer-
ence material is placed in the unused corner of the film
mammogram. The phantom is composed of two materials,
one the same density as fat and the other the same density
as fibroglandular tissue. For each pixel of the mammo-
gram, the percent density is calculated based on where
that pixel falls on the gray scale from the low-density
material to the high-density material. Total volumetric
density is then calculated as the average of these values
across all breast pixels. Total breast volume is calculated
based on the distance between the X-ray source and detec-
tor and an algorithm that takes into account the tilt of the
source/detector and the shape of the compressed breast.
This method has been shown to be highly reproducible
[4], and to be at least as strongly associated with breast
cancer risk as traditionally estimated PMD [5]. We used
the average PMD of the right and left breasts. For women
who only had a value for PMD on one side, we used the
measurement from the side with data.
Selection of women with high and low adjusted percent
mammographic density
We used age-adjusted and BMI-adjusted PMD to select
participants for the genetic study. We square root-trans-
formed PMD to make the data less skewed (Figure S1 in
Additional File 1) and then used a linear regression model
to calculate the association between age, BMI, and square
root-transformed PMD. We used the residuals of this
model as the adjusted PMD value for each woman. We
selected 500 women with adjusted PMD in the highest
quintile and 500 women with adjusted PMD in the lowest
quintile for genotyping. Of these, we were able to identify
494 corresponding biospecimens from women in the top
quintile and 489 biospecimens from women in the bottom
quintile. All 1,000 women were linked to the California
Cancer Registry by the San Francisco Mammography Reg-
istry annually since 2004 to confirm the women did not
develop breast cancer after their screening examination.
Genotyping
The samples were genotyped on the Illumina 1 M plat-
form at the Center for Inherited Disease Research. A total
of 40 samples were excluded from further analysis because
they were unexpected duplicates of other samples (n = 7),
they did not perform well in genotyping (n = 25), they did
not cluster with European samples in principal component
analysis (PCA) (n = 4) (Figure S2 in Additional File 1),
they appeared in the dataset as both a high-density sample
and a low-density sample (n = 1), they were found to be
unexpected full siblings of other samples (n = 2), or they
did not have an associated phenotype (n = 1) (Table S1 in
Additional File 1), leaving 474 women with high adjusted
PMD and 469 women with low adjusted PMD. Of the
1,043,142 SNPs genotyped, 45,933 were excluded from
further analysis because they had no position information,
they were mitochondrial or on the Y-chromosome,
they were intensity-only or technical failures, or they
had greater than 10% failed genotyping (Table S2 in
Additional File 1).
Statistical analyses
We used t tests and Wilcoxon rank-sum tests for continu-
ous variables and used chi-square tests for categorical vari-
ables to determine whether there were significant
differences between women with high adjusted PMD and
women with low adjusted PMD for baseline characteristics
and principal components (PCs).
We performed PCA using EIGENSTRAT [34]. To infer
ancestry, we included publicly available [35,36] genotype
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datasets from European and Middle Eastern samples with
known ancestry: Italians (n = 14), Tuscans (n = 8), Basque
(n = 24), French (n = 29), Orcadians (n = 16), Russians
(n = 27), Adygei (n = 17), Sardinians (n = 28), Spanish
(n = 12), Ashkenazi Jews (n = 21), and Palestinians (n =
51). For the combined PCA analysis, we used a subset of
390,144 SNPs that were genotyped on both the Illumina 1
M platform and the other Illumina platforms used in the
reference datasets. Changing the European and Middle
Eastern groups did not substantially change the first princi-
pal component (PC1) (data not shown). For visualization of
results in Figure 1, we selected the ancestry groups that
most closely corresponded in the PC space to the Cauca-
sian American women of our sample; these groups
included the Italians, Tuscans, French, Orcadians, Russians,
Adygei, Spanish, and Ashkenazi Jews.
We performed analysis of shared extended haplotypes
(identity by descent (IBD)) using GERMLINE [37]. We
defined a shared extended haplotype as being at least
three centimorgans long, the default setting for GERM-
LINE. Prior to running GERMLINE we phased the
genotype data and imputed missing genotypes using
BEAGLE [38]. We calculated 95% confidence intervals
(CIs) of the mean shared IBD between groups, as well as
P values comparing two different means, using bootstrap-
ping, resampling 1,000 times.
We performed multivariate logistic regression analysis
on the outcome of high versus low adjusted PMD to assess
whether the association between position on PC1 and
adjusted PMD remained significant after adjusting for
baseline characteristics using Stata software (version 10.0;
Stata Corporation, 4905 Lakeway Dr., College Station, TX,
77845). For this analysis, we performed a linear transfor-
mation on PC1 in order to quantify the percent Ashkenazi
Jewish ancestry on a scale of approximately 0 to 1:
(Value of PC1− 0.0309) /− 0.1102
After this transformation, a PC1 value of -0.0793
became 1.0, corresponding to the highest value of Ashke-
nazi Jewish ancestry in our sample, and a PC1 value of
0.1102 became 0.0 and was associated with the greatest
Figure 1 Principal component analysis of participants from our study and additional reference samples of known ancestry. The first
principal component (PC1) separates people of Ashkenazi Jewish ancestry from other European groups. The vertical dotted lines separate the
Ashkenazi Jewish and Northern European clusters from the middle group. The diagonal dotted line divides the probably mixed Ashkenazi-other
European group (higher values on the second principal component (PC2)) from the Southern European group (lower values on PC2).
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distance along PC1 from individuals of Ashkenazi Jewish
ancestry.
Results
Characteristics of women with high versus low adjusted
percent mammographic density
The mammographic and epidemiologic characteristics of
women with high versus low age-adjusted and BMI-
adjusted PMD are presented in Table 1. Unadjusted PMD
and volume of mammographic density were significantly
higher and total breast volume was lower in women with
high adjusted PMD. Postmenopausal women were more
likely to have lower adjusted PMD. Women with high
adjusted PMD were more likely to have reported a family
history of breast cancer.
BMI was significantly higher in women with high
adjusted PMD by the Wilcoxon rank-sum test, but not by
the t test (P = 0.6). Our initial method of adjusting PMD
for BMI assumed a linear relationship between BMI and
PMD, while the relationship is in fact nonlinear, especially
at higher BMI values (Figure S3 in Additional File 1).
Women with higher BMI values were therefore over-
represented in the group with higher adjusted PMD.
Identification of population substructure
We performed PCA to determine the population substruc-
ture of our sample. First we performed PCA with popula-
tions of European, African, Asian, American, and Oceanian
descent to verify the Caucasian ancestry of our sample
population. Of the 951 women included in the initial analy-
sis, four women appeared to have a possible admixture
with Asian or African ancestry (Figure S2 in Additional File
1). To simplify the analysis, we excluded these women from
additional analyses. Next, we performed the PCA again
with only the population that clustered with European
ancestry and incorporated publicly available genotyped
samples from European and Middle Eastern populations of
known ancestry (Figure 1). PC1 separated people of Ashke-
nazi Jewish ancestry from other European groups. Exclud-
ing the ancestral populations had no effect on PC1; the
correlation of the component scores of PC1 when including
versus excluding these samples of known ancestry was
r2 = 1.0. The second PC reflected Northern versus South-
ern European ancestry (Figure 1). When we excluded the
ancestral populations, the component scores of the third
PC were highly correlated with the component scores of
the second PC with ancestral populations (r2 = 0.88).
Ashkenazi Jews have a significantly higher proportion
of their genome that is IBD than other Caucasian
populations [39,40]. We therefore performed analysis of
IBD in our sample. We first defined two clusters in the PC
space: a probable Northern European cluster (Group 1)
with PC1 ≥0.005 and a probable Ashkenazi Jewish cluster
(Group 4) with PC1 ≤-0.0495 (Figure 1). Group 1 repre-
sented 65.7% of the total Caucasian sample and Group 4
represented 15.8%. We compared the degree of IBD
among pairs of women within each of the groups. The
pairs of individuals in Group 4 averaged 23.2 centimorgans
Table 1 Characteristics of women with high adjusted percent mammographic density versus low adjusted percent
mammographic density
High adjusted PMD Low adjusted PMD P value
Percent dense tissue by volume 72.7 (13.3) 29.6 (6.4) <10-3
Volume of dense breast tissue (ml) 327.3 (215.0) 166.2 (70.2) <10-3
Volume of the breast (ml) 479.1 (354.6) 576.5 (242.9) <10-3
Age (years) 52.4 (9.7) 51.7 (7.8) 0.9
Body mass index (kg/m2) 24.1 (6.5) 23.9 (3.1) <10-3
Age at first live birth 0.1
<30 years 96 (20%) 114 (24%)
≥30 years or nulliparous 378 (80%) 354 (76%)
Unknown 0 1
Menopausal status
Premenopausal 203 (43.3%) 159 (34.3%)
Postmenopausal 157 (33.5%) 183 (39.4%) 0.009*
Postmenopausal on hormone therapy 71 (15.1%) 77 (16.6%) 0.7**
Unknown 38 (8.1%) 45 (9.7%)
First-degree relative with breast cancer 0.02
Yes 114 (24%) 84 (18%)
No 366 (76%) 383 (82%)
Unknown 0 2
Data presented as mean (standard deviation) or n (%). PMD, percent mammographic density. Chi-squared P values calculated excluding the samples with
unknown values. *P value for comparison with premenopausal women. **P value for comparison with postmenopausal women not taking hormone therapy.
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of shared haplotypes compared with 6.0 centimorgans in
the pairs from Group 1 (bootstrap P < 10-3), consistent
with the hypothesis that Group 4 represented women of
Ashkenazi Jewish descent.
Ashkenazi Jewish ancestry is associated with high
adjusted percent mammographic density
We examined the association between PCs from the
genetic ancestry analysis and adjusted PMD. We identified
a significant association between PC1 and adjusted PMD
(P = 0.004). Comparing the distributions of PC1 values
between women with high and low adjusted PMD, we
found that women with low PC1 values were over-repre-
sented in the high adjusted PMD group and women with
high PC1 values were over-represented in the low adjusted
PMD group (Figure 2). Using transformed values of PC1,
with 0 representing the least amount of Ashkenazi Jewish
ancestry as measured by PCA and 1 representing the
greatest, having a PC1 value of 1 corresponded to an odds
ratio (OR) of 2.0 for having high adjusted PMD. To adjust
for the nonlinear relationship between BMI and PMD, we
re-adjusted for BMI by quartiles (Table 2) and by deciles
(Table S3 in Additional File 1) in multivariate analysis.
The multivariate adjusted OR for the association of PC1
and adjusted PMD after adjusting for BMI by quartiles is
2.2 (95% CI = 1.4 to 3.6). The same OR after adjusting for
BMI by deciles is 2.2 (95% CI = 1.3 to 3.6). We also ana-
lyzed our data by clustering women into subgroups based
on the PCA results (Figure 1). The group of women that
clustered with Ashkenazi Jews (Group 4) had an OR of
1.60 (P = 0.01; Table S4 in Additional File 1) of having
high adjusted PMD compared with the group of women
who clustered Northern Europeans (Group 1).
The seventh PC was also associated with adjusted PMD
(P = 0.03), although we were unable to identify a correla-
tion with an ancestral population and the seventh PC. The
third PC (which corresponded to the second PC in the
analysis with the ancestral populations and separated
Northern versus Southern European ancestry) did not cor-
relate with adjusted PMD (P = 0.3). Table S5 in Additional
File 1 presents the correlation of each of the first 10 PCs
with adjusted PMD.
Adjusting for the known epidemiologic and mammo-
graphic characteristics of the women in our sample did not
attenuate the association between Ashkenazi Jewish ances-
try and high adjusted PMD (Table 2). The OR for a woman
with the most Ashkenazi Jewish ancestry, as defined by
PCA, having high adjusted PMD versus low adjusted PMD
remained approximately 2. We adjusted for two additional
variables outside the model shown in Table 2: breast
volume and family history of breast cancer in a first-degree
relative. Adjusting for the association between PC1 and
breast volume moderately increased the significance of the
association between PC1 and adjusted PMD (OR = 2.26,
95% CI = 1.41 to 3.62, P = 0.001). Adjusting for family his-
tory of breast cancer did not attenuate the association (OR
= 1.98, 95% CI = 1.25 to 3.14, P = 0.004).
We performed additional analyses on individuals
whose genetics suggested partial Ashkenazi Jewish
ancestry to determine whether partial Ashkenazi Jewish
ancestry was also associated with increased adjusted
PMD. We examined the individuals who fell between
Figure 2 Position along the first principal component correlates with risk of high/low adjusted percent mammographic density. P value
of association between the first principal component and percent mammographic density (PMD) obtained using the Wilcoxon rank-sum test.
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Group 1 (Northern European ancestry) and Group 4
(Ashkenazi Jewish ancestry) on PC1 (Figure 1). The sec-
ond PC with the ancestral populations included divided
this middle group into individuals who clustered with
known Southern European groups (Group 2) and indivi-
duals who did not (Group 3). The IBD pattern in indivi-
duals in Group 3 supported our hypothesis that this
group reflected an admixture between people of Ashke-
nazi Jewish ancestry and European ancestry, with Group
3 having higher within-group IBD than Group 2 as well
as higher between-group IBD with Group 4 than did
Group 2 (Table S6 in Additional File 1).
We compared the probability of having high adjusted
PMD between the group with mixed Ashkenazi Jewish
ancestry (Group 3) and the group with Southern Eur-
opean ancestry (Group 2). We adjusted this analysis for
PC1 since women in Group 3 had slightly lower values
on PC1 than did Group 2 (-0.02 vs. -0.01; P = 0.0007).
We found significantly higher probability of high
adjusted PMD among Group 3 compared with Group 2
(OR = 2.10; 95% CI = 1.05 to 4.21). This finding
suggests that having partial Ashkenazi Jewish ancestry
may contribute to an increased risk of having high
adjusted PMD.
Discussion
We performed an analysis of genetic ancestry and age-
adjusted and BMI-adjusted PMD, a strong risk factor for
breast cancer. We found that the highest value of Ashke-
nazi Jewish ancestry, as identified by PCA, was associated
with a twofold greater risk of having an adjusted PMD in
the top quintile. When we analyzed women by clusters of
ancestry, women who clustered with Ashkenazi Jews had a
1.6-fold greater likelihood of having higher adjusted PMD
compared with women who clustered with Northern Eur-
opeans. This association was independent of total breast
volume, parity, menopausal status, and postmenopausal
hormone therapy. In addition, women who are likely to
have partial Ashkenazi Jewish ancestry by PCA and IBD
analysis also had higher adjusted PMD.
The identification of an ethnic group with higher
adjusted PMD has significant implications for strategies to
identify the genetic basis of this trait. Ashkenazi Jews have
probably undergone a population bottleneck followed by
rapid expansion, consistent with being a founder popula-
tion [41,42]. Founder populations are more likely to have
unique variants that are otherwise absent or exceptionally
rare in other populations [43-46]. Since a genome-wide
association study has only identified variants that account
for <1% of the variance in adjusted PMD [30], but adjusted
PMD is estimated to be approximately 60% heritable
[24-27], the vast majority of heritability for adjusted PMD
remains unexplained. Our finding suggests that women of
Ashkenazi Jewish ancestry may have unique genetic var-
iant(s) or higher frequencies of variants that predispose to
higher adjusted PMD.
Although a genetic effect is a plausible explanation for
the higher adjusted PMD in Ashkenazi Jewish women,
we cannot rule out unmeasured nongenetic confounders.
We adjusted for some factors known to be associated with
PMD including age at parity, menopausal status, and use
of postmenopausal hormone therapy. However, we did
not adjust for other factors such as age at menarche or
number of children. The finding that women of partial
Ashkenazi Jewish ancestry also have higher adjusted PMD
supports a genetic basis for the increased adjusted PMD in
Table 2 Multivariate regression of baseline characteristics and the first principal component with adjusted percent
mammographic density
Univariate analyses Multivariate analysis
Odds ratio (95% confidence interval) P value Odds ratio (95% confidence interval) P value
First principal component 2.00 (1.26 to 3.17) 0.003 2.22 (1.36 to 3.65) 0.002
Body mass index
First quartile (<21 kg/m2) Reference Reference
Second quartile (21 to 23 kg/m2) 0.41 (0.28 to 0.59) <0.001 0.38 (0.26 to 0.57) <0.001
Third quartile (23 to 26 kg/m2) 0.33 (0.23 to 0.49) <0.001 0.31 (0.21 to 0.46) <0.001
Fourth quartile (>26 kg/m2) 0.44 (0.30 to 0.63) <0.001 0.48 (0.32 to 0.71) <0.001
Age at first live birth
<30 years Reference Reference
≥30 years or nulliparous 1.27 (0.93 to 1.72) 0.1 1.13 (0.80 to 1.59) 0.5
Menopausal status
Premenopausal Reference Reference
Postmenopausal 0.67 (0.50 to 0.90) 0.009 0.67 (0.49 to 0.92) 0.01
Postmenopausal on hormone therapy 0.72 (0.49 to 1.06) 0.1 0.74 (0.49 to 1.10) 0.1
Odds ratios are for likelihood of having high adjusted percent mammographic density compared with low adjusted percent mammographic density. Univariate
and multivariate P values are calculated using chi-squared tests.
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Ashkenazi Jews, although it is also possible that women of
mixed Ashkenazi Jewish descent are exposed to the same
environmental factors as women of Ashkenazi Jewish
descent.
One limitation of our study is that we did not have
information about whether these women self-identified as
Ashkenazi Jews. However, other genetic studies with self-
identification information have identified Ashkenazi Jews
as a cluster among US Caucasians [47,48]. Furthermore,
individuals who self-identify as having partial Ashkenazi
Jewish ancestry can also been identified by PCA [49].
Another limitation of our study was that our analysis
depended on both the measurement of PMD using the
SXA approach and on a sampling scheme that sampled
the top and bottom quintiles. The SXA measurement of
PMD is known to have high reproducibility [6] and has
been associated with breast cancer risk [5]. In addition, we
found an association between high adjusted PMD and
family history of breast cancer, as has previously been
observed with qualitative measures of breast density
[50,51]. However, it is possible that the association
between adjusted PMD and genetic ancestry is only appar-
ent when measuring PMD using SXA and is an artifact of
that method; additional studies of PMD and ancestry will
be necessary to confirm that the association remains when
different methods are used to measure PMD. In addition,
our analysis sampled the top and bottom quintiles of age-
adjusted and BMI-adjusted PMD. The association between
genetic ancestry and this trait may be due to a differential
effect of age or BMI on PMD in Ashkenazi Jews compared
with other Caucasians. We calculated the BMI using self-
reported height and weight, which can underestimate high
BMI values and overestimate low BMI values [52].
Finally, our adjustment for the effect of BMI on PMD as
part of the sampling did not completely eliminate the
association between PMD and BMI. We noted an associa-
tion between BMI and adjusted PMD, even after we had
adjusted PMD for BMI. We believe this association was
due to a nonlinear relationship between BMI and PMD,
especially at higher BMIs. We therefore stratified by BMI
quartile and by decile and re-adjusted for BMI in the mul-
tivariate analysis using these categories, and did not detect
any attenuation of the main association between ancestry
and adjusted PMD. Future studies of PMD may benefit
from adjusting for BMI initially by categories rather than
using a linear regression to avoid having to adjust twice.
The Ashkenazi Jewish population has been reported to
have higher rates of breast cancer compared with other
Caucasian populations [53], which may be at least par-
tially explained by its high prevalence of two founder
mutations in BRCA1 and one founder mutation in
BRCA2 [54]. However, the increased prevalence of
BRCA1 and BRCA2 germline mutation carriers is unli-
kely to explain the association of adjusted PMD with
Ashkenazi Jewish ancestry, as two studies have demon-
strated no association between BRCA1 or BRCA2 muta-
tion status and PMD [55,56]. Based on our data we
cannot determine whether increased PMD in Ashkenazi
Jewish women is associated with an increased risk of
breast cancer independent of BRCA1 and BRCA2.
Ashkenazi Jews may have higher PMD because of genetic
or environmental factors that increase PMD but have no
impact on breast cancer risk. Alternatively, higher PMD
in Ashkenazi Jews may result from previously unknown
genetic risk factors for breast cancer development.
Conclusions
In summary, women of Ashkenazi Jewish ancestry are
more likely to have high age-adjusted and BMI-adjusted
PMD. Environmental risk factors, genetic variation, or
both may explain this finding. Ashkenazi Jews are a foun-
der population with substantially higher IBD compared
with other populations. One or more genetic variant(s)
unique to this population may therefore increase PMD.
Further research is needed to uncover potential genetic
determinants underlying the higher adjusted PMD in this
group, which in turn may shed new light on the biologic
mechanisms of PMD.
Additional material
Additional file 1: Table S1 describes the number of samples
excluded from the analysis and the reasons they were excluded.
Table S2 describes the number of SNPs excluded from the analysis and
the reasons they were excluded. Table S3 includes the analysis of
association between PC1 and PMD by quartiles and deciles of BMI. Table
S4 demonstrates the association between PMD and population
subgroups (Groups 1 to 4) rather than using continuous PCs as
predictors. Table S5 lists the P values for associations between PMD and
the top ten PCs. Table S6 demonstrates the pairwise average IBD
segment sharing between pairs of women from different subgroups.
Figure S1 demonstrates the distribution of PMD before and after
transformations and the thresholds for sampling top and bottom
quintiles. Figure S2 demonstrates the distribution of genetic ancestry of
samples from our study in comparison with populations with ancestry
from Africa, Europe, East Asia, and America. Figure S3 demonstrates the
distribution of PMD in relation to BMI.
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